The exceptional cash printing abilities of Clinuvel were on show...

The exceptional cash printing abilities of Clinuvel were on show again this week with results exceeding all analyst forecasts and coming in at NPAT up 16% to ~ $36 Million, following on from last years cracker of NPAT up 47% to ~ $30 Million and giving eight consecutive years of profits. CUV control most expenses very well and it would seem likely they will deliver similar growth again next year which is higher than companies like CSL and COH have forecast yet they trade on P/Es of double or more than CUV - historically CUV has had a much higher P/E than lately. There is no way CSL or COH have the ability to explode revenues and profits by many multiples in just a few years as CUV could well do if Vitiligo is approved as a new indication to an already FDA approved drug.

Since last years great profit result CUV has been very heavily shorted each and every day on the ASX. ASIC data shows how shorters have pumped in more than 3% new open short positions in one year to bring the total open shorts to 6.3% in this lightly traded and tightly held stock. This is number 25 in the ASX and higher than any other Biotech, far higher than most and lumped in with many loss making companies. Clinuvel is doing better than ever right now yet thanks to extreme shorting is sitting at 5 year lows in SP and they are squarely facing a 2nd board strike in just weeks after an extremely strong 1st strike last year. I don't see how they are going to avoid that as shorters have been allowed to write the narrative for far too long and some weird communications in the past have not helped things.

So let's look at the best comparison stock to CUV in Disc Medicine. They are targeting the EPP market with their lead drug (which flunked a Phase 2 this year). That is the EPP market which Clinuvel absolutely monopolises and will monopolise for years to come yet cash burning Disc is now valued at ~$2.3 Billion AUD which is TRIPLE cash printing CUV market cap despite the possibility Disc may never achieve an FDA approval? This is strange to me because they are outperforming Clinuvel for Investment despite a much increased spend from CUV in CBM this year. Even last night Disc was up over 4% on normal enormous volume while CUV (CLVLY) actually fell on just a couple of thousand shares traded. I'm not sure what CUV investor relations are getting wrong here, obviously shorting is very effective but maybe they need to headhunt Disc IR experts? Last night Disc made this announcement that they will have some ' fireside chats' at the following conferences:

• 2024 Wells Fargo Securities Healthcare Conference on Friday, September 6^th

• Morgan Stanley 22^nd Annual Global Healthcare Conference on Friday, September 6^th

• H.C. Wainwright 26^th Annual Global Investment Conference on Wednesday, September 11^th

• 2024 Cantor Global Healthcare Conference on Thursday, September 19^th

That is pretty good going by Disc, four big conferences in less than 2 weeks and who knows how many hundreds of millions it will add to the Disc market cap. Does anyone know if Clinuvel is also participating at these conferences, it would seem pretty clear when these two companies are presented side by side that CUV is a screaming Buy? Clinuvel has the enormous, and quite likely, Vitiligo transformation event in just a few years as just one of many opportunities on their medical side. Then there is the cosmetic side with products that will contain melanocortins to provide tanning and assist DNA repair and they are openly talking about the excitement and being a household name in two years which in my opinion is going to come from these products. Yet why can't they outperform Disc or at least match them?

All IMO DYOR